GT Biopharma heads into its May 15 earnings report with short sellers stepping up pressure on a stock already down more than half its value this year.
Short interest is the defining story here. It jumped 43% in a single week to 9% of the free float — a sharp reversal from a month-long unwinding that had cut positions by 16%. That week-over-week surge is the fastest build in the past six weeks and brings shorts back toward levels seen in early April. The stock closed at $0.34 on Monday, off 8.6% on the day and down 10% across the past week, leaving it roughly 52% below where it started 2026.
The borrowing market tells a more nuanced story. Cost to borrow has roughly halved since late March, falling from above 22% to around 9% — meaning shorts are paying less to maintain their positions than at any point in the prior two months. Availability, however, remains meaningful: the lending pool is only about one-third drawn down, well below the 52-week maximum when borrow was fully consumed. That combination — rising short interest alongside falling borrow cost and loose availability — suggests the build reflects fresh conviction from short sellers rather than a technically forced position.
The fundamental backdrop is sparse. GT Biopharma generates no revenue, with the latest estimated net loss running near $10.6 million. The only analyst coverage on record — a Roth MKM Buy initiation from December 2024 with an $11 target — is too stale to carry weight against a stock trading at $0.34, and the market cap is now below $12 million. The ORTEX short score sits at 50, roughly mid-range, consistent with a stock where the bear case is present but not at an extreme. The analyst-implied return potential of nearly 700% reflects solely how far the stock has fallen from that dated target, not a live market consensus.
Historical earnings reactions have been consistently negative. The last three prints produced a -7.1%, -1.7%, and -5.8% one-day move, with the five-day trajectory often deteriorating further. The May 15 report is therefore less a debate about growth and more a test of whether the pipeline narrative can hold against a balance sheet that has been burning cash with nothing yet flowing back in.
See the live data behind this article on ORTEX.
Open GTBP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
